EHR-embedded OCDT in Breast or GI Cancer

Last updated: May 11, 2022
Sponsor: Dana-Farber Cancer Institute
Overall Status: Completed

Phase

N/A

Condition

Chemotherapy

Breast Cancer

Stomach Cancer

Treatment

N/A

Clinical Study ID

NCT03858712
18-571
  • Ages > 18
  • All Genders

Study Summary

This is research study is for participants with advanced breast or gastrointestinal cancer who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy). This study is to help researchers better understand gaps in assessing oral chemotherapy patient toxicity at home, adherence to treatment and integrate toxicity/adherence reporting.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult age 18 or older

  • Male or Female

  • Scheduled visit at DF/HCC within the BOC or GCC

  • Diagnosis of advanced breast cancer or gastrointestinal cancer

  • Prescribed any OCDT within prior 5 days of screening

  • English as the primary language (as documented in the EHR, written or spoken, and patient interpreter needed flag = no)

  • Mobile number listed in EHR to allow participation in ePP portion of the study

  • Women of any pregnancy status

  • Patients diagnosed with an advanced cancer will be eligible to participate in the study until discontinuation of OCDT or death, whichever occurs first

Exclusion Criteria

  • Adults unable to provide verbal consent

  • Pediatric patients

  • Patients without access to a electronic device (including tablet, computer, aptop or smartphone)

Study Design

Total Participants: 100
Study Start date:
March 13, 2019
Estimated Completion Date:
November 23, 2021

Study Description

For patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.

  • Participants will complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice

  • Participants between clinic visits, will be asked to complete the oral weekly survey at home via the mobile or web based patient portal. The survey can be completed on a computer, tablet or smartphone at home or on a tablet at the time of scheduled visit.

    • The first 100 participants to complete the survey will receive a passive care team alert for responses (per DFHCC policy)

    • The second 100 participants to complete the survey will receive an active care team alert for responses.

Connect with a study center

  • Dana Farber Cancer Institute

    Boston, Massachusetts 02115
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.